TheraRadar
← Back
Data updated: Jun 28, 2026

PHARMA SERVE NY

Generics
Pharmaceuticals

PHARMA SERVE NY is a generic drug manufacturer with 3 FDA-approved products.

1980
Since
3
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

Upcoming FDA Decisions

Full Calendar →
Aug 10, 2026 — Oveporexton (TAK-861)
30d
Aug 19, 2026 — Garetosmab
Aug 23, 2026 — DTX401 (pariglasgene brecaparvovec)
+2 more dates (Pro)

PHARMA SERVE NY's Key Drugs

PHARMA SERVE NY's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

PHARMA SERVE NY's Recent FDA Approvals

New NDA/BLA approvals for PHARMA SERVE NY over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

PHARMA SERVE NY's Therapeutic Areas

Disease areas where PHARMA SERVE NY has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

PHARMA SERVE NY Pipeline Snapshot

Active clinical trials for PHARMA SERVE NY across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling